| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.6 |
| mRNA | BRD-K27188169 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.6 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | ouabain | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.6 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | 0.026 | 0.6 |